Endocrinology Medical News about Pamidronate

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Long-Term Effects of Pamidronate in Thalassemic Patients with Severe Bone Mineral Density Deficits
Hemoglobin, 10/23/09

Leung TF et al. – Osteoporosis is a common complication in thalassemia major (TM). Our previous study demonstrated severe bone mineral density (BMD) deficits at spine and hip in 62 and 35% of TM patients. This study assessed the effects of different treatments (calcium, vitamin D and bisphosphonate) on patients' BMD, which was measured at baseline and after 3–year treatments by dual energy X–ray absorptiometry (DEXA). Long–term improvement in BMD in TM patients was observed with bisphosphonate but not calcium and vitamin D treatment.

<< Previous
Hyperglycemia Management in Non-critically Ill Hospitalized...

Next >>
Retinal arteriolar narrowing increases the likelihood of chronic...